Latest News
Updates from Drug Programs in Clinical Trials
At the Annual SMA Conference, representatives from six of the seven programs currently in clinical trials gave an update on their programs. Of these six programs, four—gene therapy, ISIS-SMNRx, RG7800, […]
Read More ›2015 SMA Researcher Meeting Summary: Emerging Trends in Motor Neuron Pathobiology
We will be posting a series of summaries from our 2015 researcher meeting, highlighting some of the most interesting new developments and discoveries presented there. This update covers the special […]
Read More ›House of Representatives Passes 21st Century Cures
The House of Representatives has passed 21st Century Cures. Cure SMA is proud to support this legislation. Thank you for your calls and tweets to voice your support to your […]
Read More ›Seven Individuals and Families Recognized for Their Contributions to the Community
Each year, while much of our community is gathered together, we use the Annual SMA Conference to recognize several individuals, families and foundations who have provided special support to the […]
Read More ›Cytokinetics Releases Update on Phase 1 Trial at Annual SMA Conference
At last week’s Annual SMA Conference, Cytokinetics released additional data from their Phase 1 study of CK-2127107, a skeletal muscle activator. Cytokinetics, in partnership with Astellas, has already announced that […]
Read More ›Isis Announces Additional Trial Results at Annual SMA Conference
At last week’s Annual SMA Conference, Isis Pharmaceuticals, Inc. provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMNRx […]
Read More ›